Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

Inclusion Criteria:

- At screening has suspected or confirmed CDI, and is receiving or is planning to
receive a 10- to 21-day course of antibacterial drug treatment for CDI

- At study infusion has a diagnosis of CDI confirmed by a diagnostic assay which detects
the presence of C. difficile toxin in stool, and is still receiving antibacterial drug
treatment for CDI.

- Female is not pregnant, and not breastfeeding; but if of childbearing potential agrees
to follow contraceptive guidance during the treatment period and for at least 12 weeks
after the last dose of study treatment

- Participant and/or parent or caregiver must be able to read, understand, and complete
the daily diary

Exclusion Criteria:

- Has an uncontrolled chronic diarrheal illness

- Has a known hypersensitivity to bezlotoxumab, its active substance and/or any of its
excipients

- At randomization, their planned course of antibacterial drug treatment for CDI is
longer than 21 days

- At screening has received any listed prohibited prior and concomitant treatments and
procedures

- Has previously participated in this study, has previously received bezlotoxumab, has
received an experimental monoclonal antibody against C. difficile toxin B, or has
received a vaccine directed against C. difficile or its toxins.

- Has received an investigational study agent within the previous 30 days, or is
currently participating in or scheduled to participate in any other clinical study
with an investigational agent during the 12-week study period